Researchers at Shandong University in China have engineered the probiotic bacterium E. coli Nissle 1917 to function as a living drug factory inside tumors. The modified bacteria produce Romidepsin (FK228), an FDA-approved anticancer compound, directly at tumor sites. In mouse models with breast cancer, the engineered probiotics successfully accumulated inside tumors and released the drug under controlled conditions.
The approach represents a shift from traditional chemotherapy, which floods the entire body with toxic drugs. By delivering medication precisely where it is needed, the bacterial system could reduce side effects while increasing the drug concentration at the tumor. The study, published March 17 in PLOS Biology, showed the bacteria worked effectively in both laboratory and live animal settings.
The research is still in early stages and has not been tested in humans. Future studies will need to evaluate safety, potential side effects, and strategies for removing the bacteria after treatment is complete.
